$Atnm Actimab-A plus Venetoclax : changing the treatment paradigm for AML patients $rhhby $jnj $bmy $mrk $pfe $abbv $amgn $gild $sny $gsk $vrtx $sgen $bmrn $halo $tgtx $tril #Pennystocks @genentech $aveo https://t.co/2JoT7gY55T